Abstract
The importation of arbovirus diseases into countries where they are not currently endemic is a global concern, driven by human movement and direct and indirect climate change effects. In the World Health Organization Eastern Mediterranean region, three countries - the Republic of Djibouti, the Federal Republic of Somalia, and the Republic of Yemen - are currently considered to be at potential or moderate risk for yellow fever outbreaks, and an assessment for outbreak potential in the event of importation was sought. Djibouti and Somalia share land borders and significant cross-border movement with countries where yellow fever is endemic, while Yemen is currently experiencing a crisis which has severely impacted healthcare infrastructure, and has already seen suspected outbreaks of other similar arboviruses such as dengue, chikungunya and West Nile.
Here we present a mathematical modelling assessment of the risk of introduction and propagation of yellow fever in Djibouti, Somalia and Yemen. This modelling has two components: projecting the risk of importation of infectious individuals into individual administrative regions of the countries of interest, and the use of a dynamic yellow fever model to model yellow fever virus transmission within the same regions.
We present results showing that certain regions of Djibouti, Somalia and Yemen are at higher risk than others for yellow fever outbreaks, with the risk being higher in some areas such as the western coastal regions of Yemen (an area that has experienced recent outbreaks of other arboviruses), regions of Somalia bordering both the Federal Democratic Republic of Ethiopia and the Republic of Kenya, and Djibouti City.
Competing Interest Statement
This research was carried out as part of the Vaccine Impact Modelling Consortium (VIMC), and funded in whole, or in part, by the Bill & Melinda Gates Foundation (Grant Number INV-034281, previously OPP1157270 / INV-009125) Gavi, the Vaccine Alliance and the Wellcome Trust (Grant ID: 226727 Z 22 Z). For the purpose of open access, under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. The views expressed are those of the authors and not necessarily those of the Consortium or its funders. The funders of the study had no role in data collection, data analysis, data interpretation, study design, or writing of the report. The funders were given the opportunity to review this paper prior to publication, but the final decisions on content, and to submit the paper for publication, were taken by the authors. KF and KAMG received funding from Gavi, BMGF and/or the Wellcome Trust via VIMC during the course of the study. KF and KAMG also acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. KAMG reports speaker fees from Sanofi Pasteur outside the submitted work. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A - ethics approval and consent were not required
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
